Vitamin E study
This article was originally published in The Tan Sheet
Vitamin E along with use of Hoechst-Roussel's ACE inhibitor Altace (ramipril) will be investigated in the prevention of heart attacks, strokes, peripheral vascular disease and death in high risk patients under a four-year, 9,000-patient trial set to begin July 1. The $11 mil. Heart Outcomes Prevention Evaluation (HOPE) trial is being funded by the Medical Research Council of Canada, Hoechst-Roussel and Upjohn, which comarkets Altace in the U.S. Eastman Chemical, Henkel Fine Chemicals and Eisai USA will provide the vitamin E for the trial. HOPE includes 228 sites in the U.S., Canada, Europe and South America
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC